mTNBC timeline to Cure:
Sept. 9th, 2024 Letter.
I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center. We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors. The Company intends to use this preclinical study to form the basis for a potential partnership and better inform the design of a follow-up clinical study in patients with metastatic TNBC.
Dec. 17th, 2024 Letter:
The Company will be prioritizing oncology in 2025, as we believe this indication holds the potential for the highest value return to the Company in the form of a significant partnership and/or drug approval.
* as previously announced, we are launching two preclinical studies in TNBC that will seek to further clarify the mechanism of action of leronlimab in oncology and identify potential treatment synergies to optimize the design of a follow-up clinical study.
Feb. 24th, 2025:
the Company confirmed that a small group of patients who failed treatment after developing metastatic disease survived more than 36 months after receiving leronlimab, are alive today, and currently identify as having no evidence of ongoing disease.
Based on these survival observations, the Company has initiated two pre-clinical studies in mTNBC that will evaluate possible treatment synergies between leronlimab, an antibody-drug complex treatment (sacituzumab govitecan),
_____
Gilead: (sacituzumab govitecan)
Black Box drug Trodelvy.
All 267 passed away @ 21 months in ASCENT.
Collapse this link: Trodelvy chp . com
_____
" I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.”
Between Dec. 17th, 2024 & Feb. 24th, 2025 trials were started.
Everything falling right in-line with the 48 month follow-up of our ladies who are surviving mTNBC as disease free.
Disease free confirmed again & Cytodyn declares to the world, 1st ever cancer cure through Leronlimab:
Cure for Metastatic Cancer
NED ( No Evidence of Disease )
Sept. 9th, 2024 Letter.
I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center. We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors. The Company intends to use this preclinical study to form the basis for a potential partnership and better inform the design of a follow-up clinical study in patients with metastatic TNBC.
Dec. 17th, 2024 Letter:
The Company will be prioritizing oncology in 2025, as we believe this indication holds the potential for the highest value return to the Company in the form of a significant partnership and/or drug approval.
* as previously announced, we are launching two preclinical studies in TNBC that will seek to further clarify the mechanism of action of leronlimab in oncology and identify potential treatment synergies to optimize the design of a follow-up clinical study.
Feb. 24th, 2025:
the Company confirmed that a small group of patients who failed treatment after developing metastatic disease survived more than 36 months after receiving leronlimab, are alive today, and currently identify as having no evidence of ongoing disease.
Based on these survival observations, the Company has initiated two pre-clinical studies in mTNBC that will evaluate possible treatment synergies between leronlimab, an antibody-drug complex treatment (sacituzumab govitecan),
_____
Gilead: (sacituzumab govitecan)
Black Box drug Trodelvy.
All 267 passed away @ 21 months in ASCENT.
Collapse this link: Trodelvy chp . com
_____
" I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.”
Between Dec. 17th, 2024 & Feb. 24th, 2025 trials were started.
Everything falling right in-line with the 48 month follow-up of our ladies who are surviving mTNBC as disease free.
Disease free confirmed again & Cytodyn declares to the world, 1st ever cancer cure through Leronlimab:
Cure for Metastatic Cancer
NED ( No Evidence of Disease )
16
